Cramer Rosenthal Mcglynn LLC Grows Position in Omnicell, Inc. $OMCL

Key Points

• Cramer Rosenthal Mcglynn LLC increased its stake in Omnicell, Inc. by 27.3% in Q1, owning approximately 220,276 shares valued at $7.7 million.
• Multiple analysts have recently adjusted their price targets for Omnicell, with a consensus target of $46.71 and a rating of "Moderate Buy."
• Omnicell reported a net margin of 2.01% and earnings of $0.45 per share for the latest quarter, exceeding expectations and showing a 5.0% year-over-year revenue growth.

Cramer Rosenthal Mcglynn LLC boosted its position in shares of Omnicell, Inc. (NASDAQ:OMCL - Free Report) by 27.3% during the 1st quarter, according to the company in its most recent disclosure with the SEC. The firm owned 220,276 shares of the company's stock after buying an additional 47,245 shares during the quarter. Cramer Rosenthal Mcglynn LLC owned approximately 0.47% of Omnicell worth $7,701,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Victory Capital Management Inc. grew its position in Omnicell by 10.1% during the first quarter. Victory Capital Management Inc. now owns 1,680,347 shares of the company's stock valued at $58,745,000 after buying an additional 154,038 shares during the period. Dimensional Fund Advisors LP grew its position in Omnicell by 31.6% during the fourth quarter. Dimensional Fund Advisors LP now owns 1,642,626 shares of the company's stock valued at $73,127,000 after buying an additional 394,820 shares during the period. Lazard Asset Management LLC grew its position in Omnicell by 81.6% during the fourth quarter. Lazard Asset Management LLC now owns 1,641,817 shares of the company's stock valued at $73,093,000 after buying an additional 737,536 shares during the period. ArrowMark Colorado Holdings LLC lifted its holdings in Omnicell by 4.9% during the fourth quarter. ArrowMark Colorado Holdings LLC now owns 1,196,990 shares of the company's stock valued at $53,290,000 after purchasing an additional 56,117 shares in the last quarter. Finally, Toronto Dominion Bank purchased a new position in Omnicell during the fourth quarter valued at $30,637,000. Institutional investors and hedge funds own 97.70% of the company's stock.

Analyst Ratings Changes

A number of research analysts recently weighed in on OMCL shares. Piper Sandler decreased their price target on shares of Omnicell from $57.00 to $55.00 and set an "overweight" rating on the stock in a research note on Monday, August 11th. Benchmark decreased their target price on Omnicell from $62.00 to $40.00 and set a "buy" rating on the stock in a research report on Wednesday, May 7th. Wall Street Zen cut Omnicell from a "strong-buy" rating to a "buy" rating in a research report on Saturday, August 9th. Wells Fargo & Company raised their price objective on Omnicell from $37.00 to $40.00 and gave the company an "overweight" rating in a report on Monday, July 21st. Finally, Bank of America upped their target price on shares of Omnicell from $30.00 to $34.00 and gave the stock a "neutral" rating in a report on Friday, May 23rd. Four research analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average target price of $46.71.

Omnicell Trading Down 2.1%

NASDAQ:OMCL traded down $0.69 during trading hours on Friday, hitting $32.59. The company had a trading volume of 595,171 shares, compared to its average volume of 577,128. Omnicell, Inc. has a 1 year low of $22.66 and a 1 year high of $55.74. The company has a market cap of $1.50 billion, a P/E ratio of 65.18, a P/E/G ratio of 7.27 and a beta of 0.78. The company has a 50-day moving average of $30.07 and a 200 day moving average of $31.62. The company has a current ratio of 1.42, a quick ratio of 1.24 and a debt-to-equity ratio of 0.13.

Omnicell (NASDAQ:OMCL - Get Free Report) last announced its quarterly earnings data on Thursday, July 31st. The company reported $0.45 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.30 by $0.15. The firm had revenue of $290.56 million during the quarter, compared to analyst estimates of $275.57 million. Omnicell had a net margin of 2.01% and a return on equity of 4.27%. Omnicell's quarterly revenue was up 5.0% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.51 earnings per share. Omnicell has set its FY 2025 guidance at 1.400-1.650 EPS. Q3 2025 guidance at 0.300-0.370 EPS. Sell-side analysts expect that Omnicell, Inc. will post 1.09 earnings per share for the current year.

About Omnicell

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.